Addressing current challenges in lentiviral vector purification and associated analytics

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Addressing current challenges in lentiviral vector purification and associated analytics

As more and more engineered cell therapy products that utilize lentiviral (LV) vectors in their manufacture reach the market, the sector’s focus is sharpening around optimizing LV downstream processing. Given the significant contribution that LV vectors make to the overall cost of goods of these cell therapy products, and the importance of maximizing quality for patient safety and regulatory CMC purposes, it is imperative to maximize downstream purification efficiency and vector recovery, and to be able to harness the available analytical toolkit to demonstrate vector quality.

Here, we convene a panel of LV downstream process experts to explore current issues in the field, and discuss how they can be overcome utilizing the available LV purification and analytics toolkit.

Bryan Zee

Associate Scientist, Juno Therapeutics, Inc.

Bryan started his purification career at Amgen’s PD group where he developed several clinical stage biologics and handled a myriad of modalities such as mAbs, bispecifics, and Fc-fusion proteins. Since 2019 he’s been at BMS’s viral vector PD department where he has developed BMS’s LVV purification platform and AAV purification platform.

Anindya Dasgupta

Director of GMP at Expression

Anindya is the director of vector development at Expression Therapeutics. He obtained his PhD from University of South Carolina, USA. His post-doctoral training and research associateship at the school of medicine, Emory University, Atlanta, USA, were focussed on the evaluation of novel anti-cancer therapies and the development of strategies for expansion and lentivirus based bioengineering of gamma delta; T cells in serum free media. Anindya is a co-inventor of a patent on anti-cancer strategy. At his recent role at Cincinnati Childrens Hospital Medical Centre he led vector development to manufacture high titer lentiviral vectors.